One of these biomarkers is STAT6, which has been identified as a PPI target in EoE patients, as it is involved in drug pharmacodynamics since PPIs block STAT6 binding to the CCL26 promoter [10]. This evidence concerns the gene STAT6 and eosinophilic esophagitis.